A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

Clinical trial NCT07662720 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07662720
Sponsor: Glycyx Therapeutics
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Start date: 2026-07-15
Primary completion: 2027-08-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.